Literature DB >> 1576116

Persistent generation of thrombin after acute myocardial infarction.

A Szczeklik1, J Dropinski, J Radwan, M Krzanowski.   

Abstract

During the acute phase of myocardial infarction, the generation of thrombin is reflected in the sudden rise of fibrinopeptide A (FPA) and the thrombin-antithrombin III (TAT) complex in blood. We have systematically determined the FPA and TAT plasma concentrations over a period of 14 days after acute myocardial infarction in 100 patients. Mean levels of both thrombin markers were the highest on admission, remained elevated over the following few days, and then gradually declined after day 5. Still, by the end of the first week two thirds of the patients had distinctly elevated TAT and FPA levels, and by the end of the second week such an abnormality was present in half of them. Continuous intravenous heparin infusion at a dose of 20,000 units/day, administered for 1 week to patients who had either received (n = 21) or not received (n = 17) streptokinase, led to a significant depression (p less than 0.05) of thrombin markers over the first 48 hours, an effect that did not persist over the subsequent days of treatment. In patients not assigned to heparin treatment, those in heart failure had significantly (p less than 0.05) higher mean TAT and FPA values on days 3, 5, and 7 compared with patients in whom heart failure was absent. Infarct extension, pulmonary embolism, and death were also associated with a rise in one or both thrombin markers, often preceding the onset of clinical symptoms. Thrombinogenesis was not accompanied by changes in mean plasma concentrations of prothrombin, antithrombin III, or alpha 2-macroglobulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576116     DOI: 10.1161/01.atv.12.5.548

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  8 in total

1.  The Heparin Rebound Phenomenon-Does It Offer Insights Toward Understanding the Pathobiology of Coronary Thrombosis and Its Treatment?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Thrombin and its receptor enhance ST-segment elevation in acute myocardial infarction by activating the KATP channel.

Authors:  Ming Long; Lei Yang; Genya Huang; Liping Liu; Yugang Dong; Zhimin Du; Anli Tang; Chenghen Hu; Ruimin Gu; Xiuren Gao; Lilong Tang
Journal:  Mol Med       Date:  2010-04-09       Impact factor: 6.354

Review 3.  Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.

Authors:  G Palareti; C Legnani
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

4.  Plasma Markers of Procoagulant Activity Among Individuals with Coronary Artery Disease.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

5.  Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.

Authors:  Oliver Borst; Patrick Münzer; Nada Alnaggar; Sascha Geue; Roland Tegtmeyer; Dominik Rath; Michal Droppa; Peter Seizer; Stefan Heitmeier; Johan W M Heemskerk; Lisa K Jennings; Robert F Storey; Dominick J Angiolillo; Bianca Rocca; Henri Spronk; Hugo Ten Cate; Meinrad Gawaz; Tobias Geisler
Journal:  Blood Adv       Date:  2018-03-27

6.  Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis.

Authors:  Mauro Chiarito; Davide Cao; Francesco Cannata; Cosmo Godino; Corrado Lodigiani; Giuseppe Ferrante; Renato D Lopes; John H Alexander; Bernhard Reimers; Gianluigi Condorelli; Giulio G Stefanini
Journal:  JAMA Cardiol       Date:  2018-03-01       Impact factor: 14.676

7.  Plasma levels of thrombin and activated protein C in patients with acute myocardial Infarction: An observational study.

Authors:  Tobias Becher; Robert Schimanski; Jens Müller; Stefan Baumann; Selina Klenantz; Bernd Pötzsch; Dirk Lossnitzer
Journal:  Int J Cardiol Heart Vasc       Date:  2022-07-30

8.  Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?

Authors:  Hugo Ten Cate; H Coenraad Hemker
Journal:  J Am Heart Assoc       Date:  2016-08-08       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.